Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ST 1535 is a potent and orally active antagonist of A2A adenosine receptor with antiparkinsonian activity and antitremorigenic effects. ST 1535 exhibits the potential for the research of Parkinson’s disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 67.00 | |
5 mg | In stock | $ 143.00 | |
10 mg | In stock | $ 195.00 | |
25 mg | In stock | $ 340.00 | |
50 mg | In stock | $ 493.00 | |
100 mg | In stock | $ 719.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 148.00 |
Description | ST 1535 is a potent and orally active antagonist of A2A adenosine receptor with antiparkinsonian activity and antitremorigenic effects. ST 1535 exhibits the potential for the research of Parkinson’s disease. |
In vitro | ST-1535 competitively antagonizes the effects of the A2A adenosine agonist NECA on cAMP in cells cloned with the human A2A adenosine receptor (IC50=353+/-30 nM), and the effects of the A1 adenosine agonist CHA on cAMP in cells cloned with the human A1 adenosine receptor (IC50=510+/-38 nM). [1] |
In vivo | ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice. At oral doses ranging between 5 and 20 mg/kg, ST 1535 induces hypermotility and antagonizes haloperidol-induced catalepsy in mice up to 7 h. Oral ST 1535, at 1.25 and 2.5 mg/kg, potentiates L-dopa effects in reducing haloperidol-induced catalepsy. [1] |
Molecular Weight | 272.31 |
Formula | C12H16N8 |
CAS No. | 496955-42-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 9 mg/mL (33.05 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ST-1535 496955-42-1 GPCR/G Protein Neuroscience Adenosine Receptor ST1535 ST 1535 inhibitor inhibit